Link Immunology

Link Immunology is an early-stage biotechnology company focused on the discovery and development of novel therapies for immunological and inflammatory diseases. Headquartered in Durham, North Carolina, the company was founded by Dr. Michael Howell, a seasoned executive who previously served as Chief Scientific Officer at Dermavant Sciences, where he led the development of the FDA-approved treatment Vtama (tapinarof). The company operates primarily in stealth mode, leveraging deep expertise in cytokine signaling and dermatology to identify and validate high-impact therapeutic targets. Link Immunology aims to address significant unmet needs in chronic inflammatory conditions through innovative molecular approaches. The firm is backed by Frazier Life Sciences and is currently advancing its initial research programs toward clinical candidate selection.